Abstract 425P
Background
In Indonesia, traditional medicine is still trusted, especially as a cancer therapy. Cancer treatment, which has many side effects, triggers the patient's anxiety. The patient's decision may contradict the advice of a health professional, affecting the prognosis of cancer. Health professionals are responsible for delivering explicit and adequate information to prevent misinformation that may affect decision-making for patient care. The Universitas Sebelas Maret Trust and Readiness Assessment for Cancer Patients (UNS – TRAfCP35) is an instrument designed to assess a patient's understanding of cancer, confidence in alternative medicine, and a patient's confidence in medical therapies. This study aims to see the validity and reliability of UNS – TRAfCP35 in assessing patients' understanding of cancer, trust in alternative medicine, and trust in medical treatment for cancer patients in Indonesia.
Methods
This is a cross-sectional hospital-based study conducted on 100 patients at Dr. Moewardi Hospital, using UNS-TRAfCP35. The questionnaire consisted of 35 questions divided into 3 parts: 15 questions regarding patients' understanding of cancer, 8 questions regarding their belief in alternative medicine, and 12 questions about patients' trust in medical treatment. Validity and reliability were used using Pearson and Cronbach alpha.
Results
Validity tests showed that the understanding of cancer (r = 0.236–0.456), the patient's confidence in alternative medicine (r = 0.301–0.688) and the patient's confidence in medical care (r = 0.324–0.765) had r > 0.196. Reliability tests showed that the questions from each section had Cronbach alpha values of 0.712, 0.830, and 0.844, respectively. Alfa Cronbach > 0.60. The values indicate that all questions in the questionnaire are valid, reliable, consistent, and qualified for further analysis for the treatment of cancer patients.
Conclusions
This study shows that UNS – TRAfCP35 is valid and reliable for assessing patients' understanding of cancer, trust in alternative medicine, and medical care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06